First Trust Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$137M Buy
306,461
+105,171
+52% +$49M 0.1% 253
2025
Q4
$91.3M Buy
201,290
+13,129
+7% +$5.66M 0.07% 365
2025
Q3
$73.7M Sell
188,161
-99,731
-35% -$41.7M 0.05% 419
2025
Q2
$128M Buy
287,892
+143,084
+99% +$65.9M 0.1% 233
2025
Q1
$70.2M Sell
144,808
-47,978
-25% -$22.4M 0.06% 406
2024
Q4
$77.6M Sell
192,786
-382,246
-66% -$177M 0.07% 365
2024
Q3
$267M Buy
575,032
+371,691
+183% +$179M 0.25% 110
2024
Q2
$95.3M Sell
203,341
-27,856
-12% -$12.1M 0.1% 233
2024
Q1
$96.6M Sell
231,197
-503,638
-69% -$213M 0.1% 235
2023
Q4
$299M Sell
734,835
-63,531
-8% -$23.5M 0.33% 52
2023
Q3
$278M Buy
798,366
+508,389
+175% +$178M 0.33% 50
2023
Q2
$102M Sell
289,977
-42,809
-13% -$14.4M 0.12% 219
2023
Q1
$105M Sell
332,786
-17,185
-5% -$5.15M 0.12% 219
2022
Q4
$101M Sell
349,971
-10,921
-3% -$3.33M 0.12% 231
2022
Q3
$104M Sell
360,892
-668,540
-65% -$192M 0.14% 188
2022
Q2
$290M Buy
1,029,432
+588,620
+134% +$158M 0.36% 46
2022
Q1
$115M Sell
440,812
-80,615
-15% -$19.1M 0.12% 214
2021
Q4
$115M Buy
521,427
+30,756
+6% +$5.98M 0.11% 219
2021
Q3
$89M Buy
490,671
+91,357
+23% +$17.8M 0.1% 263
2021
Q2
$80.5M Buy
399,314
+11,734
+3% +$2.45M 0.09% 303
2021
Q1
$83.3M Sell
387,580
-16,439
-4% -$3.61M 0.1% 258
2020
Q4
$95.5M Sell
404,019
-425,744
-51% -$97.7M 0.13% 200
2020
Q3
$226M Buy
829,763
+17,708
+2% +$4.89M 0.36% 48
2020
Q2
$236M Buy
812,055
+316,633
+64% +$85.8M 0.41% 36
2020
Q1
$118M Buy
495,422
+138,446
+39% +$31.8M 0.27% 66
2019
Q4
$78.2M Sell
356,976
-89,458
-20% -$18.1M 0.13% 188
2019
Q3
$75.6M Sell
446,434
-221,798
-33% -$39.2M 0.14% 177
2019
Q2
$123M Sell
668,232
-69,332
-9% -$12.1M 0.23% 86
2019
Q1
$136M Buy
737,564
+29,086
+4% +$5.37M 0.27% 63
2018
Q4
$117M Sell
708,478
-9,977
-1% -$1.73M 0.28% 57
2018
Q3
$138M Buy
718,455
+204,780
+40% +$36.5M 0.26% 64
2018
Q2
$87.3M Buy
513,675
+36,704
+8% +$5.69M 0.18% 110
2018
Q1
$77.7M Sell
476,971
-65,461
-12% -$10.7M 0.18% 108
2017
Q4
$81.3M Sell
542,432
-12,589
-2% -$1.86M 0.19% 95
2017
Q3
$84.4M Sell
555,021
-91,518
-14% -$13.8M 0.22% 93
2017
Q2
$83.3M Buy
646,539
+243,153
+60% +$29.3M 0.22% 86
2017
Q1
$44.1M Sell
403,386
-13,906
-3% -$1.22M 0.12% 172
2016
Q4
$30.7M Buy
417,292
+57,019
+16% +$4.64M 0.09% 267
2016
Q3
$31.4M Sell
360,273
-56,288
-14% -$5.32M 0.09% 256
2016
Q2
$35.8M Sell
416,561
-17,404
-4% -$1.5M 0.11% 200
2016
Q1
$34.5M Sell
433,965
-545,760
-56% -$49.4M 0.11% 213
2015
Q4
$123M Sell
979,725
-43,619
-4% -$5.27M 0.32% 54
2015
Q3
$107M Buy
1,023,344
+22,220
+2% +$2.85M 0.31% 64
2015
Q2
$124M Buy
1,001,124
+150,498
+18% +$19M 0.32% 53
2015
Q1
$100M Sell
850,626
-165,610
-16% -$19.8M 0.29% 62
2014
Q4
$121M Buy
1,016,236
+133,010
+15% +$15M 0.41% 26
2014
Q3
$99.2M Sell
883,226
-102,926
-10% -$9.8M 0.39% 28
2014
Q2
$93.4M Buy
986,152
+198,579
+25% +$13.9M 0.39% 22
2014
Q1
$55.7M Buy
787,573
+153,849
+24% +$12.2M 0.24% 60
2013
Q4
$47.1M Sell
633,724
-26,782
-4% -$1.87M 0.23% 70
2013
Q3
$50.1M Buy
660,506
+252,451
+62% +$20.1M 0.27% 55
2013
Q2
$32.7M Buy
+408,055
New +$30.1M 0.21% 92

Other funds holding VRTX

First Trust Advisors's VRTX Position: Q1 2026 in Review

First Trust Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 52% in Q1 2026, buying an estimated $49M and bringing the position to 306,461 shares worth $137M. The position accounts for 0.1% of the portfolio, ranked #253.

First Trust Advisors first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $299M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • First Trust Advisors held 306,461 shares of Vertex Pharmaceuticals worth $137M as of Q1 2026.
  • First Trust Advisors bought 105,171 Vertex Pharmaceuticals shares in Q1 2026, an estimated $49M.
  • Vertex Pharmaceuticals made up 0.1% of First Trust Advisors's portfolio in Q1 2026, its #253 holding.
  • First Trust Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • First Trust Advisors's Vertex Pharmaceuticals position peaked at $299M in Q4 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.